A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).

• Status: Not yet recruiting
• Trial end date: 2024-04-01

Summary

This study is an open label study followed by a randomised, double-blind, placebo-controlled, parallel group and an extension study to investigate the safety and efficacy of GB1211 (a galectin-3 inhibitor) in combination with atezolizumab in patients with Non-Small Cell Lung Cancer (NSCLC).

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: Galecto Biotech AB
• Collaborators: Hoffmann-La Roche; Linical Europe GmbH
• Treatments: Atezolizumab